Company intelligence / Profile preview
Future Origins
- Ownership
- Private
- Development stage
- Commercial
Overview
Future Origins has developed NALO™, a bioengineered C12/C14 fatty alcohol that serves as a high-performing, drop-in replacement for traditional palm oil-based surfactant ingredients. The product has been independently validated for performance in personal care and cleaning applications. The company has secured major offtake agreements with Kao Corporation and is preparing to launch commercial-scale production in the United States by 2025. Several tons of purified product will be available for sampling by Q2 2025.
- Modalities
- Biologic (fermentation-derived)Small molecule (C12/C14 fatty alcohols as chemical ingredients)
- Industry
- Non-Drug Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Future Origins.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Future Origins.